We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Government Contracts and Robust Liquidity Fuel Maximus' Growth
Read MoreHide Full Article
Key Takeaways
MMS gains from government partnerships, recurring revenues, strong cash flow and steady dividend payouts.
MMS relies heavily on federal and state contracts, exposing growth to funding shifts & slowing core segments.
MMS posted Q1 EPS growth. However, its revenues missed estimates and declined year over year.
Maximus (MMS - Free Report) is benefiting from its reputation as a trusted partner to governments worldwide, delivering cost-effective, scalable solutions in health and human services. Strong shareholder-friendly policies and solid liquidity are added advantages.
Meanwhile, regulatory risk and heavy reliance on contracts from federal and state governments pose significant concerns for the company. Heightened competition within the government services industry further puts pressure on profitability and scalability.
How is MMS Faring?
Maximus gains from its business process management expertise and ability to deliver cost-effective, efficient and large-scale solutions, positioning it as a lucrative partner to governments. The company has grown to be a leading operator of government health and human services programs globally, enabling it to generate predictable recurring revenue streams. Improved quality of lifestyle and more complex health needs have increased the need for government social benefits and safety-net programs, consequently driving the company’s top-line growth.
MMS generates strong cash flow from operations, driven by its profitable operations and efficient receivables management. The subject-matter expertise of its workforce in the critical aspects of the design, implementation, and operation of government health and human services programs differentiates the company, giving it a competitive advantage over its peers.
The company consistently rewards its shareholders through dividend payments. It paid dividends of $68.7 million, $72.9 million, $68.1 million and $68.7 million in fiscal 2025, 2024, 2023 and 2022, respectively. Such moves indicate the company’s commitment to return value to shareholders and instill their confidence in the business.
MMS’s current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2026 was 2.34, higher than the industry’s 2.14. A current ratio of more than 1 indicates that the company is well-positioned to pay off its short-term obligations.
Meanwhile, Maximus continues to rely heavily on contracts from federal and state governments, particularly in programs like Medicaid and Medicare. The company is currently experiencing slowing growth in its core business segments due to this reliance. MMS’s top line and contract volume can be directly impacted by changes in government funding priorities.
The company operates in a highly regulated industry, which exposes it to significant regulatory risks. Policy shifts or changes to government healthcare programs under different political administrations could affect Maximus’s ability to win contracts or sustain existing ones. Regulatory changes that tighten requirements for contractors could increase operational costs and reduce profits.
Recently, MMS reported mixed first-quarter fiscal 2026 results. Earnings of $1.85 per share marginally beat the Zacks Consensus Estimate and increased 14.9% from the year-ago quarter. Total revenues of $1.4 billion missed the consensus estimate by 4.6% and dipped 4.1% year over year.
Earnings Snapshots of Some Other Service Providers
FTI Consulting, Inc. (FCN - Free Report) reported impressive results for the fourth quarter of 2025.
FCN’s adjusted earnings per share of $1.78 beat the consensus mark by 39 cents and increased 14.1% from the year-ago quarter. FTI Consulting’s revenues of $990.7 million beat the Zacks Consensus Estimate of $911.4 million and rose 10.7% from the year-ago quarter.
IT’s adjusted earnings were $3.94 per share, which beat the Zacks Consensus Estimate by 12.6%. The metric decreased 27.7% from the year-ago quarter. Gartner’s total revenues of $1.8 billion beat the consensus estimate by a slight margin and improved 2.2% on a year-over-year basis.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Government Contracts and Robust Liquidity Fuel Maximus' Growth
Key Takeaways
Maximus (MMS - Free Report) is benefiting from its reputation as a trusted partner to governments worldwide, delivering cost-effective, scalable solutions in health and human services. Strong shareholder-friendly policies and solid liquidity are added advantages.
Meanwhile, regulatory risk and heavy reliance on contracts from federal and state governments pose significant concerns for the company. Heightened competition within the government services industry further puts pressure on profitability and scalability.
How is MMS Faring?
Maximus gains from its business process management expertise and ability to deliver cost-effective, efficient and large-scale solutions, positioning it as a lucrative partner to governments. The company has grown to be a leading operator of government health and human services programs globally, enabling it to generate predictable recurring revenue streams. Improved quality of lifestyle and more complex health needs have increased the need for government social benefits and safety-net programs, consequently driving the company’s top-line growth.
Maximus, Inc. Revenue (TTM)
Maximus, Inc. revenue-ttm | Maximus, Inc. Quote
MMS generates strong cash flow from operations, driven by its profitable operations and efficient receivables management. The subject-matter expertise of its workforce in the critical aspects of the design, implementation, and operation of government health and human services programs differentiates the company, giving it a competitive advantage over its peers.
The company consistently rewards its shareholders through dividend payments. It paid dividends of $68.7 million, $72.9 million, $68.1 million and $68.7 million in fiscal 2025, 2024, 2023 and 2022, respectively. Such moves indicate the company’s commitment to return value to shareholders and instill their confidence in the business.
MMS’s current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2026 was 2.34, higher than the industry’s 2.14. A current ratio of more than 1 indicates that the company is well-positioned to pay off its short-term obligations.
Meanwhile, Maximus continues to rely heavily on contracts from federal and state governments, particularly in programs like Medicaid and Medicare. The company is currently experiencing slowing growth in its core business segments due to this reliance. MMS’s top line and contract volume can be directly impacted by changes in government funding priorities.
The company operates in a highly regulated industry, which exposes it to significant regulatory risks. Policy shifts or changes to government healthcare programs under different political administrations could affect Maximus’s ability to win contracts or sustain existing ones. Regulatory changes that tighten requirements for contractors could increase operational costs and reduce profits.
Recently, MMS reported mixed first-quarter fiscal 2026 results. Earnings of $1.85 per share marginally beat the Zacks Consensus Estimate and increased 14.9% from the year-ago quarter. Total revenues of $1.4 billion missed the consensus estimate by 4.6% and dipped 4.1% year over year.
Maximus currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings Snapshots of Some Other Service Providers
FTI Consulting, Inc. (FCN - Free Report) reported impressive results for the fourth quarter of 2025.
FCN’s adjusted earnings per share of $1.78 beat the consensus mark by 39 cents and increased 14.1% from the year-ago quarter. FTI Consulting’s revenues of $990.7 million beat the Zacks Consensus Estimate of $911.4 million and rose 10.7% from the year-ago quarter.
Gartner, Inc. (IT - Free Report) posted impressive fourth-quarter 2025 results.
IT’s adjusted earnings were $3.94 per share, which beat the Zacks Consensus Estimate by 12.6%. The metric decreased 27.7% from the year-ago quarter. Gartner’s total revenues of $1.8 billion beat the consensus estimate by a slight margin and improved 2.2% on a year-over-year basis.